Brief: Abbisko Cayman Says Merck's Exercise Of Global Option For Pimicotinib
01/04/2025 02:27
April 1 (Reuters) - Abbisko Cayman Ltd 2256.HK: MERCK'S EXERCISE OF GLOBAL OPTION FOR PIMICOTINIB UNDER LICENSING AGREEMENT WITH OPTION EXERCISE FEE OF USD85.0 MILLION Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly